About: Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension?
Creator	Turner, Jeffrey Kodali, Ravi
Source	Medline; PMC
abstract	PURPOSE OF REVIEW: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are commonly used anti-hypertensive medications in a number of clinical settings. They are often used interchangeably, but we pose the provocative question as to whether they should be. We review the literature to evaluate for any differences in efficacy between the two classes in order to determine if the greater side effects associated with angiotensin-converting enzyme inhibitors are offset by any advantageous effects on outcomes to warrant their use over angiotensin receptor blockers. RECENT FINDINGS: In many clinical scenarios, the data supports similar efficacy between ACE inhibitors and ARBs, while in a minority of others, there are murky signals from previous trials that suggest ACE inhibitors may be better. However, when reviewing the literature in its entirety, and taking into account recently published pooled analysis and head to head trials, it is reasonable to conclude that ACE inhibitors and ARBs have similar efficacy. This is in contrast to data on adverse effects, which consistently favors the use of ARBs. SUMMARY: From the available data, it is reasonable to conclude that ACE inhibitors and ARBs have equal efficacy yet unequal adverse effects. It is in this context that we take the provocative stance that ACE inhibitors should not be used to treat hypertension.
has issue date	2020-07-09(xsd:dateTime)
bibo:doi	10.1007/s11886-020-01352-8
bibo:pmid	32648000
has license	no-cc
sha1sum (hex)	b325326f225237a896c108e8a6722388859b4ac4
schema:url	https://doi.org/10.1007/s11886-020-01352-8
resource representing a document's title	Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension?
has PubMed Central identifier	PMC7344347
has PubMed identifier	32648000
schema:publication	Curr Cardiol Rep
resource representing a document's body	covid:b325326f225237a896c108e8a6722388859b4ac4#body_text
is schema:about of	named entity 'antihypertensive' named entity 'Management' named entity 'ARBs' named entity 'advantageous' named entity 'data' named entity 'stance' named entity 'ACE inhibitors' named entity 'efficacy' named entity 'literature' named entity 'angiotensin-converting enzyme inhibitors' named entity 'GELLER' named entity 'Hypertension' named entity 'ARBs' named entity 'ACE inhibitors' named entity 'hypertension' named entity 'angiotensin-converting enzyme inhibitors' named entity 'adverse effects' named entity 'ACE inhibitors' named entity 'HYPERTENSION' named entity 'ARBs' named entity 'perindopril' named entity 'systemic blood pressure' named entity 'ARBs' named entity 'diabetes' named entity 'blood pressure' named entity 'blood pressure' named entity 'ACE inhibitors' named entity 'amlodipine' named entity 'ARBs' named entity 'ACE inhibitors' named entity 'angioedema' named entity 'CKD' named entity 'placebo' named entity 'cardiovascular event' named entity 'RAAS' named entity 'losartan' named entity 'RAAS' named entity 'ACE inhibitors' named entity 'Tigerstedt' named entity 'ACE2' named entity 'ACE2' named entity 'ACE inhibitors' named entity 'control group' named entity 'significant difference' named entity 'Mechanism of action' named entity 'amlodipine' named entity 'blood pressure lowering' named entity 'renin' named entity 'cardiovascular morbidity' named entity 'cardiovascular' named entity 'enzyme' named entity 'ACE inhibitor' named entity 'Hypertension' named entity 'ramipril' named entity 'ACE inhibitors' named entity 'COVID-19' named entity 'ARBs' named entity 'meta-analysis' named entity 'Hypertension' named entity 'ARBs' named entity 'ACE inhibitor' named entity 'angiotensin' named entity 'angiotensinogen' named entity 'all-cause mortality' named entity 'AT2' named entity 'anti-hypertensive' named entity 'mRNA' named entity 'Bangalore' named entity 'placebo-controlled' named entity 'monotherapy' named entity 'absolute risk' named entity 'ACEi' named entity 'kidney disease' named entity 'ACE2' named entity 'network meta-analysis' named entity 'cardiovascular' named entity 'AKI' named entity 'renin' named entity 'valsartan' named entity 'ACE inhibitor'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software